https://orangebookblog.com/2026/04/30/hikma-v-vanda-oral-argument-recap/2026-04-30T19:16:00+00:00monthlyhttps://orangebookblog.com/2026/04/24/teva-v-lilly-should-not-be-read-as-creating-a-new-112-rule-for-method-of-use-claims/https://orangebookblog.com/wp-content/uploads/2026/04/headache.pngHeadache2026-04-24T15:11:03+00:00monthlyhttps://orangebookblog.com/2025/04/30/rundown-of-recent-federal-circuit-cases/https://orangebookblog.com/wp-content/uploads/2025/04/seal_of_the_united_states_court_of_appeals_for_the_federal_circuit.svg_.pngSeal_of_the_United_States_Court_of_Appeals_for_the_Federal_Circuit.svg2025-10-07T15:24:40+00:00monthlyhttps://orangebookblog.com/2025/05/13/judge-hughes-concurrence-highlights-ipr-appeal-standing-issue-for-pharma-cases/https://orangebookblog.com/wp-content/uploads/2025/05/hughes-e1658617012995-300x300-1.jpgHughes-e1658617012995-300x3002025-10-07T15:22:04+00:00monthlyhttps://orangebookblog.com/2025/10/07/early-challenges-to-ob-patents-should-it-be-used-more-often/https://orangebookblog.com/wp-content/uploads/2025/10/ptab-seal-feature.pngPTAB-seal-feature2025-10-07T15:20:03+00:00monthlyhttps://orangebookblog.com/authors/https://orangebookblog.com/wp-content/uploads/2025/09/mcandrews_logo_new.jpgmcandrews_logo_new2025-09-30T19:19:48+00:00weekly0.6https://orangebookblog.com/disclaimer/2025-09-30T19:18:31+00:00weekly0.6https://orangebookblog.com/about/2025-09-30T19:13:57+00:00weekly0.6https://orangebookblog.com/2025/09/30/switching-to-wordpress/2025-09-30T19:11:55+00:00monthlyhttps://orangebookblog.com/2020/11/02/split-federal-circuit-panel-reinstates-jury-verdict-of-induced-infringement-in-coreg-carvedilol-case/2025-09-30T19:06:09+00:00monthlyhttps://orangebookblog.com/2024/10/31/astellas-v-sandoz-post-remand-procedural-issues-following-at-risk-launch/2025-09-30T19:06:08+00:00monthlyhttps://orangebookblog.com/2024/10/07/obviousness-type-double-patenting-for-patent-term-adjusted-patents-post-allergan-and-in-re-cellect-2/2025-09-30T19:06:07+00:00monthlyhttps://orangebookblog.com/2025/01/30/almost-heaven-for-regeneron-federal-circuit-upholds-injunction-against-foreign-companies-sued-in-wes/2025-09-30T19:06:07+00:00monthlyhttps://orangebookblog.com/2025/02/13/federal-circuit-confirms-no-collateral-estoppel-from-ptab-findings-in-district-court/2025-09-30T19:06:07+00:00monthlyhttps://orangebookblog.com/2011/05/05/ftc-releases-report-on-anda-litigation-settlements-for-fy-2010/https://orangebookblog.com/wp-content/uploads/2011/05/mt_imported_image_1759258929.jpgmt_imported_image_17592589292025-09-30T19:02:10+00:00monthlyhttps://orangebookblog.com/2012/08/27/eli-lilly-co-et-al-v-teva-parenteral-medicines-et-al-no-2011-1561-fed-cir-dfsa-fdsa-fdsa/https://orangebookblog.com/wp-content/uploads/2012/08/mt_imported_image_1759258910.jpgmt_imported_image_1759258910https://orangebookblog.com/wp-content/uploads/2012/08/mt_imported_image_1759258911.jpgmt_imported_image_1759258911https://orangebookblog.com/wp-content/uploads/2012/08/mt_imported_image_1759258909.jpgmt_imported_image_17592589092025-09-30T19:01:51+00:00monthlyhttps://orangebookblog.com/2013/02/11/district-of-delaware-invalidates-claim-covering-entecavir-molecule-as-obvious/https://orangebookblog.com/wp-content/uploads/2013/02/mt_imported_image_1759258905.jpgmt_imported_image_1759258905https://orangebookblog.com/wp-content/uploads/2013/02/mt_imported_image_1759258904-1.jpgmt_imported_image_1759258904https://orangebookblog.com/wp-content/uploads/2013/02/mt_imported_image_1759258903.jpgmt_imported_image_1759258903https://orangebookblog.com/wp-content/uploads/2013/02/mt_imported_image_1759258904.jpgmt_imported_image_17592589042025-09-30T19:01:47+00:00monthlyhttps://orangebookblog.com/2014/06/22/meet-us-at-bio-2014-in-san-diego/https://orangebookblog.com/wp-content/uploads/2014/06/mt_imported_image_1759258892.jpgmt_imported_image_1759258892https://orangebookblog.com/wp-content/uploads/2014/06/mt_imported_image_1759258891.jpgmt_imported_image_17592588912025-09-30T19:01:32+00:00monthlyhttps://orangebookblog.com/2024/12/20/federal-circuit-affirms-that-inhaler-patents-cannot-be-listed-in-orange-book/2024-12-20T18:22:38+00:00monthlyhttps://orangebookblog.com/2024/11/14/federal-circuit-grapples-with-scope-of-orange-book-listings/2024-11-14T14:44:09+00:00monthlyhttps://orangebookblog.com/2024/10/17/collateral-estoppel-from-iprs-in-district-court/2024-10-17T20:34:11+00:00monthlyhttps://orangebookblog.com/2024/10/16/pto-considering-otdp-and-terminal-disclaimer-rule-change-is-there-a-compromise/2024-10-16T14:22:00+00:00monthlyhttps://orangebookblog.com/2024/10/07/obviousness-type-double-patenting-for-patent-term-adjusted-patents-post-allergan-and-in-re-cellect-1/2024-10-07T20:07:00+00:00monthlyhttps://orangebookblog.com/2024/10/04/wv-court-denies-regenerons-motion-for-pi-in-eylea-litigation/2024-10-04T14:16:30+00:00monthlyhttps://orangebookblog.com/2024/09/30/federal-circuit-rejects-sua-sponte-101-invalidation/2024-09-30T19:50:16+00:00monthlyhttps://orangebookblog.com/2024/09/30/relaunch-of-the-orange-book-blog/2024-10-03T13:30:56+00:00monthlyhttps://orangebookblog.com/2021/05/05/minerva-v-hologic-a-review-in-poetry/2021-05-05T22:02:08+00:00monthlyhttps://orangebookblog.com/2020/11/11/federal-circuit-dramatically-narrows-scope-of-proper-venue-in-paragraph-iv-litigation/2020-11-12T00:05:33+00:00monthlyhttps://orangebookblog.com/2018/04/01/judge-stark-d-del-holds-generic-label-including-patented-indication-insufficient-to-prove-inducement/2018-04-02T03:25:01+00:00monthlyhttps://orangebookblog.com/2017/10/30/ptab-grants-hospiras-request-for-rehearing-institutes-ipr-of-herceptin-patent/2017-10-31T04:05:00+00:00monthlyhttps://orangebookblog.com/2017/10/06/functional-claiming-of-antibodies-continue-to-proceed-with-caution/2017-10-06T21:34:01+00:00monthlyhttps://orangebookblog.com/2016/03/20/federal-circuit-holds-that-specific-personal-jurisdiction-exists-anywhere-an-anda-applicant-intends/2016-03-21T01:34:23+00:00monthlyhttps://orangebookblog.com/2015/11/10/federal-circuit-hands-split-decision-to-momenta-on-271g-and-271e1/2015-11-10T23:39:47+00:00monthlyhttps://orangebookblog.com/2015/05/05/amgen-wins-temporary-injunction-against-sandoz-in-landmark-biosimilars-case/2015-05-06T04:54:23+00:00monthlyhttps://orangebookblog.com/2015/04/16/aci-summit-on-us-biosimilars-munich-germany-april-20-21/2015-04-16T18:38:14+00:00monthlyhttps://orangebookblog.com/2015/04/14/case-or-controversy-exists-where-generic-manufacturer-seeks-declaratory-judgment-of-non-infringement/2015-04-15T03:34:54+00:00monthlyhttps://orangebookblog.com/2014/09/21/aci-paragraph-iv-disputes-master-symposium-chicago-september-30-october-1/2014-09-22T03:00:42+00:00monthlyhttps://orangebookblog.com/2014/08/10/federal-circuit-revives-mutuals-antitrust-counterclaims-stemming-from-temazepam-anda-litigation/2014-08-11T04:23:08+00:00monthlyhttps://orangebookblog.com/2014/07/10/aci-women-leaders-in-life-sciences-law-conference-boston-ma-july-28-29-1/2014-07-11T04:28:53+00:00monthlyhttps://orangebookblog.com/2014/06/20/aci-legal-and-regulatory-summit-on-generic-drugs-new-york-city-july-24-25/2014-06-21T02:58:21+00:00monthlyhttps://orangebookblog.com/2014/05/29/janssen-files-motion-to-dismiss-celltrions-dj-complaint-claiming-celltrion-is-trying-to-side-step-th/2014-05-29T19:40:58+00:00monthlyhttps://orangebookblog.com/2014/05/22/aci-biosimilars-conference-new-york-june-5-6/2014-05-22T22:58:55+00:00monthlyhttps://orangebookblog.com/2014/04/13/district-of-new-jersey-allows-anda-filers-declaratory-judgment-action-to-proceed-despite-covenant-no/2014-04-13T20:27:25+00:00monthlyhttps://orangebookblog.com/2014/04/07/aci-paragraph-iv-disputes-conference-new-york-april-28-28/2014-04-08T03:53:22+00:00monthlyhttps://orangebookblog.com/2014/04/03/second-biosimilar-company-files-declaratory-judgment-action-before-filing-fda-application/2014-04-03T22:48:42+00:00monthlyhttps://orangebookblog.com/2014/02/10/federal-circuit-affirms-validity-of-pfizers-lyrica-pregabalin-patent/2014-02-11T05:50:00+00:00monthlyhttps://orangebookblog.com/2014/01/27/bloomberg-bna-aia-post-grant-patent-practice-conference-arlington-va-february-19-20/2014-01-27T23:40:24+00:00monthlyhttps://orangebookblog.com/2014/01/24/cphi-pharma-ipr-india-2014-conference-mumbai-india-february-26-28/2014-01-24T17:58:06+00:00monthlyhttps://orangebookblog.com/2014/01/09/ptab-institutes-inter-partes-review-of-oracea-doxycycline-formulation-patents/2014-01-09T14:08:23+00:00monthlyhttps://orangebookblog.com/2013/12/22/aci-patent-reform-conference-new-york-city-january-22-23/2013-12-23T04:53:32+00:00monthlyhttps://orangebookblog.com/2013/12/18/divided-federal-circuit-panel-strikes-down-galdermas-patents-as-obviousin-shifting-the-burden-of-pro/2013-12-19T05:00:00+00:00monthlyhttps://orangebookblog.com/2013/12/08/momentum-events-ip-counsel-exchange-for-biosimilar-applicants-and-sponsors-new-york-january-23-24/2013-12-09T02:59:31+00:00monthlyhttps://orangebookblog.com/2013/12/02/exela-enjoined-from-producing-generic-version-of-ofirmev-pain-reliever-until-scr-pharmatops-patents/2013-12-02T22:16:57+00:00monthlyhttps://orangebookblog.com/2013/11/20/ptab-finds-315b-barred-petition-for-inter-partes-review-challenging-claims-amended-in-reexamination/2013-11-21T05:35:12+00:00monthlyhttps://orangebookblog.com/2013/11/14/motion-to-amend-pleadings-to-assert-inequitable-conduct-denied-in-rapamycin-case/2013-11-15T03:48:38+00:00monthlyhttps://orangebookblog.com/2013/11/12/district-court-dismisses-sandozs-declaratory-judgment-complaint-relating-to-biosimilar-enbrel/2013-11-13T00:12:48+00:00monthlyhttps://orangebookblog.com/2013/11/04/ptab-finds-counterclaims-alleging-infringement-within-315b-and-declines-to-institute-inter-partes-re/2013-11-05T03:52:14+00:00monthlyhttps://orangebookblog.com/2013/10/03/ptab-declines-to-institute-inter-partes-review-of-alimta-pemetrexed-patent/2013-10-03T23:12:51+00:00monthlyhttps://orangebookblog.com/2013/09/27/aci-paragraph-iv-disputes-master-symposium-chicago-october-3-4/2013-09-27T21:41:30+00:00monthlyhttps://orangebookblog.com/2013/09/17/invalidity-due-to-public-use-in-anda-cases/2013-09-18T02:33:26+00:00monthlyhttps://orangebookblog.com/2013/08/30/41st-ipo-annual-meeting-boston-september-15-17/2013-08-31T02:18:09+00:00monthlyhttps://orangebookblog.com/2013/08/19/momentum-international-congress-on-paragraph-iv-litigation-new-york-city-september-23-24/2013-08-20T04:39:23+00:00monthlyhttps://orangebookblog.com/2013/07/01/aci-legal-and-regulatory-summit-on-generic-drugs-new-york-city-july-17-18/2013-07-02T03:35:33+00:00monthlyhttps://orangebookblog.com/2013/06/26/federal-circuit-holds-that-good-faith-belief-of-invalidity-can-be-a-defense-to-inducement/2013-06-27T01:40:56+00:00monthlyhttps://orangebookblog.com/2013/06/20/aci-advanced-summit-on-global-patenting-strategy-practice-new-york-city-july-15-16/2013-06-21T04:05:01+00:00monthlyhttps://orangebookblog.com/2013/06/19/federal-circuit-affirms-obviousness-of-novo-nordisks-prandin-patent/2013-06-20T04:56:28+00:00monthlyhttps://orangebookblog.com/2013/06/17/supreme-court-decides-that-reverse-payment-settlements-shall-be-subjected-to-rule-of-reason-antitrus/2013-06-18T04:45:00+00:00monthlyhttps://orangebookblog.com/2013/06/16/supreme-court-holds-that-isolation-of-dna-does-not-confer-patent-eligibility-under-35-usc-101/2013-06-16T22:32:40+00:00monthlyhttps://orangebookblog.com/2013/05/24/aci-4th-advanced-forum-on-biosimilars-new-york-city-june-5-7/2013-05-25T02:17:30+00:00monthlyhttps://orangebookblog.com/2013/05/02/aci-paragraph-iv-disputes-conference-new-york-city-may-7-8/2013-05-03T00:15:22+00:00monthlyhttps://orangebookblog.com/2013/03/13/defective-complaint-triggers-30-month-stay/2013-03-14T03:49:36+00:00monthlyhttps://orangebookblog.com/2013/02/27/district-of-new-jersey-considers-subject-matter-jurisdiction-where-no-paragraph-iv-certification-is/2013-02-28T05:53:00+00:00monthlyhttps://orangebookblog.com/2013/02/27/federal-circuit-addresses-sufficiency-of-factual-support-needed-to-show-undue-experimentation/2013-02-28T05:27:00+00:00monthlyhttps://orangebookblog.com/2013/02/25/momenta-pharmaceuticals-files-supreme-court-petition-in-271e1-safe-harbor-case/2013-02-26T05:26:00+00:00monthlyhttps://orangebookblog.com/2013/02/21/federal-circuit-confirms-that-a-sales-agent-is-not-a-third-party-to-trigger-early-entry-under-a-sett/2013-02-22T03:20:40+00:00monthlyhttps://orangebookblog.com/2013/02/19/supreme-court-to-hear-argument-in-bowman-v-monsanto-post-argument-panel-discussion-and-webinar-to-fo/2013-02-19T06:05:00+00:00monthlyhttps://orangebookblog.com/2013/02/13/cphi-pharma-ipr-india-2013-conference-mumbai-india-april-10-12/2013-02-14T05:20:06+00:00monthlyhttps://orangebookblog.com/2013/02/05/novo-nordisk-requests-fda-advisory-opinion-concerning-orange-book-listing-of-patents-on-pre-filled-d/2013-02-06T02:16:08+00:00monthlyhttps://orangebookblog.com/2013/02/03/dispatch-from-india/2013-02-04T05:49:55+00:00monthlyhttps://orangebookblog.com/2013/01/28/research-universities-file-amicus-brief-in-support-of-affirming-the-federal-circuit-in-bowman-v-mons/2013-01-28T14:36:28+00:00monthlyhttps://orangebookblog.com/2012/12/06/product-hopping-the-ftc-weighs-in/2012-12-07T04:34:51+00:00monthlyhttps://orangebookblog.com/2012/11/30/aci-paragraph-iv-disputes-conference-san-francisco-december-4-5/2012-12-01T04:37:00+00:00monthlyhttps://orangebookblog.com/2012/11/20/the-america-invents-act-basic-information-for-patent-owners-and-inventors/2012-11-20T23:26:42+00:00monthlyhttps://orangebookblog.com/2012/09/28/aci-maximizing-pharmaceutical-patent-life-cycles-conference-new-york-october-10-11/2012-09-29T00:50:04+00:00monthlyhttps://orangebookblog.com/2012/08/08/internal-federal-circuit-struggle-over-scope-of-271e1-safe-harbor-continues/2012-08-09T04:40:48+00:00monthlyhttps://orangebookblog.com/2012/08/03/business-of-biosimilars-generic-drugs-conference-boston-ma-september-10-12/2012-08-03T18:49:35+00:00monthlyhttps://orangebookblog.com/2012/07/20/obb-news-briefs/2012-07-20T21:52:36+00:00monthlyhttps://orangebookblog.com/2012/07/17/3rd-circuit-issues-landmark-decision-in-pay-for-delay-case-setting-up-supreme-court-review/2012-07-23T16:37:15+00:00monthlyhttps://orangebookblog.com/2012/07/02/federal-circuit-again-vacates-preliminary-injunction-in-metformin-case/2012-07-03T04:37:43+00:00monthlyhttps://orangebookblog.com/2012/06/22/5th-product-and-pipeline-enhancement-for-generics-conference-washington-dc-july-18-19/2012-06-23T04:07:02+00:00monthlyhttps://orangebookblog.com/2012/06/15/aci-hatch-waxman-boot-camp-san-diego-june-25-26/2012-06-16T04:59:00+00:00monthlyhttps://orangebookblog.com/2012/06/12/genzyme/2012-06-13T04:50:47+00:00monthlyhttps://orangebookblog.com/2012/04/20/aci-3rd-advanced-forum-on-biosimilars-new-york-may-22-23/2012-04-21T04:57:58+00:00monthlyhttps://orangebookblog.com/2012/04/18/federal-circuit-affirms-dismissal-of-bayers-inducement-claims-in-yasmin-case/2012-04-19T04:48:14+00:00monthlyhttps://orangebookblog.com/2012/04/17/supreme-court-sides-with-generic-pharmaceutical-companies-in-dispute-over-patent-orange-book-use-cod/2012-04-18T03:28:49+00:00monthlyhttps://orangebookblog.com/2012/04/12/federal-circuit-affirms-unenforceability-of-taxotere-patents/2012-04-13T01:25:29+00:00monthlyhttps://orangebookblog.com/2012/03/21/supreme-court-speaks-on-patent-eligibility-of-diagnostic-method-claims/2012-03-21T20:20:52+00:00monthlyhttps://orangebookblog.com/2012/03/16/aci-paragraph-iv-disputes-conference-new-york-april-24-25/2012-03-16T23:32:11+00:00monthlyhttps://orangebookblog.com/2012/03/01/district-of-delaware-paragraph-iv-certification-not-required-for-jurisdiction-under-section-271e2-or/2012-03-02T04:27:33+00:00monthlyhttps://orangebookblog.com/2012/02/17/aci-life-sciences-collaborative-agreements-and-ma-conference-new-york-february-27-28/2012-02-18T03:49:33+00:00monthlyhttps://orangebookblog.com/2012/02/09/federal-circuit-section-viii-statement-avoids-infringement-under-271e2/2012-02-10T05:42:28+00:00monthlyhttps://orangebookblog.com/2012/02/09/fda-issues-draft-guidance-on-biosimilars/2012-02-09T19:50:59+00:00monthlyhttps://orangebookblog.com/2012/01/22/cephalon-ordered-to-pay-anchens-attorney-fees-for-maintaining-suit-despite-no-evidence-of-infringeme/2012-01-22T22:47:48+00:00monthlyhttps://orangebookblog.com/2011/12/16/aci-patent-reform-for-life-sciences-companies-conference-new-york-jan-31-feb-1/2011-12-16T21:00:57+00:00monthlyhttps://orangebookblog.com/2011/12/14/federal-circuit-vacates-preliminary-injunction-entered-against-mylan-in-doxycycline-case/2011-12-15T05:06:09+00:00monthlyhttps://orangebookblog.com/2011/12/07/discounted-registration-for-cphi-pharma-ipr-india-2012-expiring-soon/2011-12-08T04:01:51+00:00monthlyhttps://orangebookblog.com/2011/12/01/federal-circuit-affirms-invalidity-of-tevas-patent-on-rosuvastatin-formulation/2011-12-02T05:22:00+00:00monthlyhttps://orangebookblog.com/2011/11/03/district-of-delaware-rules-that-api-manufacturer-cannot-be-sued-as-a-defendant-under-section-271e2/2011-11-03T16:55:25+00:00monthlyhttps://orangebookblog.com/2011/10/31/cphi-pharma-ipr-india-2012-conference-mumbai-india-january-31-to-february-2-2012/2011-10-31T21:39:59+00:00monthlyhttps://orangebookblog.com/2011/10/21/aci-advanced-forum-on-biotech-patents-conference-boston-nov-30-dec-1/2011-10-21T19:29:45+00:00monthlyhttps://orangebookblog.com/2011/09/18/the-america-invents-act-a-three-page-guide-and-detailed-presentation/2011-09-19T03:43:54+00:00monthlyhttps://orangebookblog.com/2011/08/31/federal-circuit-confines-271e1-safe-harbor-to-pre-approval-activities/2011-09-01T04:56:19+00:00monthlyhttps://orangebookblog.com/2011/08/31/federal-trade-commission-issues-final-report-on-authorized-generic-drugs/2011-08-31T23:36:24+00:00monthlyhttps://orangebookblog.com/2011/08/28/federal-circuit-affirms-dismissal-of-factor-viii-priority-case-for-lack-of-interfering-subject-matte/2011-08-29T04:42:14+00:00monthlyhttps://orangebookblog.com/2011/08/26/federal-circuit-affirms-summary-judgment-of-nonobviousness-of-fortical-formulation/2011-08-26T22:12:23+00:00monthlyhttps://orangebookblog.com/2011/08/05/federal-circuit-affirms-validity-of-argatroban-patent/2011-08-05T21:20:17+00:00monthlyhttps://orangebookblog.com/2011/08/04/aci-maximizing-pharmaceutical-patent-lifecycles-conference-new-york-october-4-5/2011-08-04T21:17:52+00:00monthlyhttps://orangebookblog.com/2011/07/31/federal-circuit-confirms-that-isolated-dna-may-be-patented/2011-08-09T17:27:48+00:00monthlyhttps://orangebookblog.com/2011/07/28/federal-circuit-affirms-judgment-of-no-doe-infringement-in-cenestin-case/2011-07-29T03:09:26+00:00monthlyhttps://orangebookblog.com/2011/07/14/federal-circuit-affirms-summary-judgment-of-invalidity-for-obviousness-in-temazepam-case-1/2011-07-14T20:40:34+00:00monthlyhttps://orangebookblog.com/2011/07/07/federal-circuit-allows-district-court-injunction-of-mylans-generic-amrix-cyclobenzaprine-sales-to-stand/2011-07-07T23:50:23+00:00monthlyhttps://orangebookblog.com/2011/07/07/federal-circuit-allows-pars-appeal-of-declaratory-judgment-decision-to-proceed-in-asacol-litigation/2011-07-07T20:57:46+00:00monthlyhttps://orangebookblog.com/2011/06/30/eisai-v-teva-pharms-usa-no-10-1070-us-2011-briefs-eisai-cert-petition-teva-opposition-brief-eisai-reply-brie/2011-07-01T15:29:07+00:00monthlyhttps://orangebookblog.com/2011/06/26/fda-grants-baxters-petition-for-second-30-month-stay-relating-to-suprane-desflurane/2011-07-23T02:24:35+00:00monthlyhttps://orangebookblog.com/2011/06/07/us-supreme-court-confronts-inducement-of-infringement-under-section-271b-for-the-first-time-what-doe/2011-06-08T04:24:00+00:00monthlyhttps://orangebookblog.com/2011/05/30/obama-administration-urges-supreme-court-to-grant-cert-in-case-on-orange-book-patent-use-codes/2011-05-31T04:49:11+00:00monthlyhttps://orangebookblog.com/2011/05/27/aipla-chemical-patent-practice-road-show-prosecution-and-litigation-strategies-chicago-il-june-23/2011-05-28T01:00:15+00:00monthlyhttps://orangebookblog.com/2011/05/25/therasense-in-this-case-the-court-unabashedly-states-that-it-is-reining-in-inequitable-conduct-because-to-do-so-is-in-the-i/2011-05-26T03:52:37+00:00monthlyhttps://orangebookblog.com/2011/05/22/district-court-grants-tro-against-mylans-generic-amrix-after-finding-patents-invalid/2011-05-25T05:48:55+00:00monthlyhttps://orangebookblog.com/2011/05/20/aci-biosimilars-conference-new-york-city-june-7-8/2011-05-20T23:26:00+00:00monthlyhttps://orangebookblog.com/2011/05/15/mylan-launches-generic-amrix-cephalon-files-motion-for-tro/2011-05-16T04:07:02+00:00monthlyhttps://orangebookblog.com/2011/05/13/aci-life-sciences-collaborative-agreements-and-acquisitions-conference-san-francisco-ca-july-20-21/2011-05-14T03:47:01+00:00monthlyhttps://orangebookblog.com/2011/05/13/aci-hatch-waxman-boot-camp-conference-san-diego-ca-july-18-19/2011-05-13T22:09:13+00:00monthlyhttps://orangebookblog.com/2011/05/12/district-court-decides-amrix-cyclobenzaprine-litigation-in-favor-of-anda-filers-finding-claims-of-pa/2011-05-12T23:34:58+00:00monthlyhttps://orangebookblog.com/2011/05/10/ftc-posts-friendly-reminder-to-please-send-them-your-anda-litigation-settlement-agreements/2011-05-16T22:50:52+00:00monthlyhttps://orangebookblog.com/2011/05/02/district-court-dismisses-mylans-complaint-against-fda-concerning-generic-lipitor/2011-05-03T03:08:07+00:00monthlyhttps://orangebookblog.com/2011/05/01/book-review-the-generic-challenge-understanding-patents-fda-and-pharmaceutical-life-cycle-management/2011-05-01T21:02:32+00:00monthlyhttps://orangebookblog.com/2011/04/24/mcandrews-held-malloy-and-volker-vossius-to-co-host-patent-law-symposia-in-chicago-and-munich/2011-04-24T21:35:19+00:00monthlyhttps://orangebookblog.com/2011/04/20/district-court-set-to-decide-whether-ranbaxy-forfeited-its-180-day-exclusivity-on-generic-lipitor/2011-04-25T13:43:50+00:00monthlyhttps://orangebookblog.com/2011/04/15/federal-circuit-authorizes-narrowing-reissue-patents-that-only-add-dependent-claims/2011-04-15T22:30:17+00:00monthlyhttps://orangebookblog.com/2011/04/08/aci-paragraph-iv-disputes-conference-new-york-city-may-3-4/2011-04-09T01:56:07+00:00monthlyhttps://orangebookblog.com/2011/04/07/ive-moved/2011-04-26T21:53:10+00:00monthlyhttps://orangebookblog.com/2010/12/16/district-court-dismisses-astrazenecas-patent-suits-against-crestor-rosuvastatin-anda-applicants-who-filed-section-viii-sta/2010-12-17T01:35:41+00:00monthlyhttps://orangebookblog.com/2010/11/14/astrazeneca-defeats-tevas-claim-that-crestor-infringes-tevas-patent/2012-01-31T11:18:44+00:00monthlyhttps://orangebookblog.com/2010/11/10/federal-circuit-holds-abraxis-lacked-standing-in-ropivacaine-case-sidestepping-interesting-questions-of-jurisdiction-under-2/2010-11-11T05:18:05+00:00monthlyhttps://orangebookblog.com/2010/11/04/by-slimmest-of-margins-federal-circuit-declines-to-rehear-gemzar-gemcitibine-double-patenting-case/2010-11-05T04:13:45+00:00monthlyhttps://orangebookblog.com/2010/10/28/federal-circuit-denies-andrx-mandamus-petition-in-omeprazole-litigation/2010-10-29T04:23:00+00:00monthlyhttps://orangebookblog.com/2010/10/11/declaratory-judgment-jurisdiction-for-subsequent-paragraph-iv-filers/2010-10-12T04:45:29+00:00monthlyhttps://orangebookblog.com/2010/09/09/aci-maximizing-pharmaceutical-patent-life-cycles-conference-new-york-city-october-6-7/2010-09-10T03:25:29+00:00monthlyhttps://orangebookblog.com/2010/07/28/federal-circuit-affirms-invalidity-of-lillys-gemzar-patent-for-obviousness-type-double-patenting/2010-07-30T18:00:25+00:00monthlyhttps://orangebookblog.com/2010/07/27/dc-district-court-sides-with-fdahospirateva-against-sanofi-aventis-in-eloxatin-case/2010-07-28T04:56:55+00:00monthlyhttps://orangebookblog.com/2010/07/21/apotex-establishes-declaratory-judgment-jurisdiction-in-lipitor-patent-challenge-threatening-the-pfizer-ranbaxy-settlement/2010-07-22T21:22:13+00:00monthlyhttps://orangebookblog.com/2010/05/10/federal-circuit-upholds-patent-term-extensions-in-levaquin-and-metvixia-cases/2010-05-11T04:18:00+00:00monthlyhttps://orangebookblog.com/2010/05/02/orange-book-blog-at-bio/2010-05-05T18:55:28+00:00monthlyhttps://orangebookblog.com/2010/04/28/federal-circuit-affirms-invalidity-of-concerta-patent-for-lack-of-enablement/2010-05-08T19:37:00+00:00monthlyhttps://orangebookblog.com/2010/04/25/dr-reddys-wins-attorneys-fees-from-astrazeneca-in-prilosec-otc-case/2010-04-26T04:10:20+00:00monthlyhttps://orangebookblog.com/2010/04/19/district-court-declines-to-stay-integrelin-case-putting-teva-at-risk-of-forfeiting-180-day-exclusivity/2010-04-19T18:00:26+00:00monthlyhttps://orangebookblog.com/2010/04/15/federal-circuit-vacates-injunction-that-directed-novo-nordisk-to-revise-orange-book-patent-use-code-for-prandin/2010-04-16T04:16:04+00:00monthlyhttps://orangebookblog.com/2010/03/31/aci-paragraph-iv-disputes-conference-new-york-april-27-28/2010-04-01T04:55:03+00:00monthlyhttps://orangebookblog.com/2010/02/14/walking-the-enablementnon-obviousness-tightrope/2010-03-01T16:36:08+00:00monthlyhttps://orangebookblog.com/2009/09/11/aci-maximizing-pharmaceutical-patent-life-cycles-conference-new-york-october-78/2009-09-12T03:51:04+00:00monthlyhttps://orangebookblog.com/2009/08/05/federal-circuit-affirms-invalidity-of-bayer-patent-on-yasmin/2009-10-05T09:19:48+00:00monthlyhttps://orangebookblog.com/2009/07/15/acis-fda-boot-camp-coming-to-chicago-and-boston/2009-07-16T04:22:31+00:00monthlyhttps://orangebookblog.com/2009/04/28/supreme-court-denies-aventis-cert-petition-in-lovenox-case/2009-04-29T03:26:11+00:00monthlyhttps://orangebookblog.com/2009/02/24/federal-circuit-affirms-extension-of-30-month-stay-against-tevas-generic-evista/2009-02-25T14:52:52+00:00monthlyhttps://orangebookblog.com/2008/12/15/sanofi-prevails-over-apotex-in-plavix-appeal/2008-12-16T05:51:00+00:00monthlyhttps://orangebookblog.com/2008/12/09/federal-circuit-affirms-168-million-award-of-fees-to-takeda-in-pioglitazone-case/2008-12-11T02:56:36+00:00monthlyhttps://orangebookblog.com/2008/11/16/ftc-roundtable-competition-issues-involving-follow-on-biologic-drugs-washington-november-21/2008-11-16T23:17:00+00:00monthlyhttps://orangebookblog.com/2008/11/07/aci-paragraph-iv-on-trial-conference-new-york-november-19-20/2008-11-07T22:51:00+00:00monthlyhttps://orangebookblog.com/2008/10/17/bna-pharmaceutical-patent-laws-conference-arlington-va-november-12/2008-10-18T04:39:00+00:00monthlyhttps://orangebookblog.com/2008/10/12/c5-eu-pharma-law-and-regulation-conference-geneva-november-4-5/2008-10-13T03:46:01+00:00monthlyhttps://orangebookblog.com/2008/10/09/federal-circuit-affirms-dismissal-of-declaratory-judgment-counterclaims-in-trusoptcosopt-case/2008-10-10T03:58:29+00:00monthlyhttps://orangebookblog.com/2008/10/06/federal-circuit-affirms-dismissal-of-prascos-declaratory-judgment-suit-against-medicis/2008-10-07T04:10:02+00:00monthlyhttps://orangebookblog.com/2008/10/01/non-patent-exclusivity-and-180-day-exclusivity-forfeiture-slides-posted/2011-04-30T18:24:45+00:00monthlyhttps://orangebookblog.com/2008/09/26/cbi-paragraph-iv-disputes-conference-philadelphia-october-15-16/2008-09-27T04:12:17+00:00monthlyhttps://orangebookblog.com/2008/09/21/aci-maximizing-pharmaceutical-patent-life-cycles-conference-new-york-october-15-16/2008-09-22T03:33:20+00:00monthlyhttps://orangebookblog.com/2008/09/05/aci-fda-boot-camp-conference-boston-september-22-23/2008-09-06T02:43:36+00:00monthlyhttps://orangebookblog.com/2008/08/06/federal-circuit-narrows-the-scope-of-the-section-271e1-research-exemption/2008-08-07T04:54:00+00:00monthlyhttps://orangebookblog.com/2008/08/03/district-court-denies-early-motion-for-rule-11-sanctions-in-ritalin-la-case/2008-08-04T04:39:00+00:00monthlyhttps://orangebookblog.com/2008/07/31/aci-biotech-patents-conference-boston-september-15-16/2008-08-01T03:28:04+00:00monthlyhttps://orangebookblog.com/2008/07/21/federal-circuit-affirms-validity-and-enforceability-of-eisais-compound-patent-on-aciphex/2008-07-22T04:37:45+00:00monthlyhttps://orangebookblog.com/2008/07/20/obb-news-briefs-1/2008-07-21T03:31:20+00:00monthlyhttps://orangebookblog.com/2008/07/18/c5-biotech-patenting-conference-london-september-23-24/2008-07-19T03:44:56+00:00monthlyhttps://orangebookblog.com/2008/07/16/federal-circuit-vacates-dismissal-of-delaratory-judgment-counterclaims-in-fosamax-case-as-moot/2008-07-16T21:58:54+00:00monthlyhttps://orangebookblog.com/2008/07/13/astrazeneca-wins-seroquel-case-on-summary-judgment-teva-and-sandoz-to-appeal/2008-07-13T14:26:46+00:00monthlyhttps://orangebookblog.com/2008/07/09/federal-circuit-affirms-acular-ls-decision-in-favor-of-roche-and-allergan-and-against-apotex/2008-09-12T08:55:39+00:00monthlyhttps://orangebookblog.com/2008/07/08/book-review-generic-pharmaceutical-patent-and-fda-law/2008-07-08T15:51:15+00:00monthlyhttps://orangebookblog.com/2008/07/06/obb-news-briefs-2/2008-07-07T04:27:03+00:00monthlyhttps://orangebookblog.com/2008/07/03/in-a-surprising-victory-barr-and-mylan-invalidate-boehringer-ingelheims-patent-on-mirapex/2009-08-24T20:19:15+00:00monthlyhttps://orangebookblog.com/2008/07/01/after-court-victory-over-fda-teva-receives-final-approval-of-risperidone-anda-and-launches-with-180-day-exclusivity/2008-07-02T03:13:25+00:00monthlyhttps://orangebookblog.com/2008/06/30/mutual-pharmaceutical-jumps-the-gun-by-sending-paragraph-iv-notice-letter-before-acceptance-of-anda/2008-07-01T04:41:30+00:00monthlyhttps://orangebookblog.com/2008/06/25/fda-denies-king-pharmas-citizen-petition-concerning-altace-approves-ramipril-andas/2008-06-26T03:39:51+00:00monthlyhttps://orangebookblog.com/2008/06/24/federal-circuit-refuses-to-rehear-caraco-v-forest/2008-06-24T16:36:49+00:00monthlyhttps://orangebookblog.com/2008/06/11/mylan-prevails-over-astrazeneca-in-appeal-of-prilosec-case/2008-06-12T03:22:12+00:00monthlyhttps://orangebookblog.com/2008/06/01/obb-news-briefs-3/2008-06-02T04:05:10+00:00monthlyhttps://orangebookblog.com/2008/05/28/c5-pharma-paten/2008-05-29T03:01:24+00:00monthlyhttps://orangebookblog.com/2008/05/26/on-eve-of-180-d/2008-05-28T20:26:27+00:00monthlyhttps://orangebookblog.com/2008/05/21/patent-litigation-under-a-future-biosimilars-act/2008-05-22T16:17:06+00:00monthlyhttps://orangebookblog.com/2008/05/18/obb-news-briefs-4/2008-05-19T03:54:07+00:00monthlyhttps://orangebookblog.com/2008/05/16/iir-generic-dru/2008-05-16T19:49:47+00:00monthlyhttps://orangebookblog.com/2008/05/14/federal-circuit/2008-11-04T19:15:38+00:00monthlyhttps://orangebookblog.com/2008/05/11/gpha-files-amic/2008-05-12T04:12:39+00:00monthlyhttps://orangebookblog.com/2008/05/07/aci-fda-boot-ca/2008-05-08T03:05:24+00:00monthlyhttps://orangebookblog.com/2008/05/04/pharma-news-bri/2008-05-05T04:58:41+00:00monthlyhttps://orangebookblog.com/2008/05/02/aci-4th-annual/2008-05-03T04:28:00+00:00monthlyhttps://orangebookblog.com/2008/04/29/barr-and-caraco/2008-04-30T02:49:55+00:00monthlyhttps://orangebookblog.com/2008/04/28/wbr-pharmabiote/2008-04-29T03:46:35+00:00monthlyhttps://orangebookblog.com/2008/04/27/apotes-sues-fda/2008-04-28T04:57:44+00:00monthlyhttps://orangebookblog.com/2008/04/24/district-cour-1/2008-04-28T12:44:09+00:00monthlyhttps://orangebookblog.com/2008/04/22/aci-paragraph-i/2008-04-23T00:09:23+00:00monthlyhttps://orangebookblog.com/2008/04/21/district-court/2008-04-22T04:11:04+00:00monthlyhttps://orangebookblog.com/2008/04/18/pharma-news-bri-2/2008-04-19T03:38:23+00:00monthlyhttps://orangebookblog.com/2008/04/15/informa-life-sc/2008-04-16T03:09:44+00:00monthlyhttps://orangebookblog.com/2008/04/01/federal-circuit-2/2008-04-01T17:20:27+00:00monthlyhttps://orangebookblog.com/2008/03/31/federal-circu-2/2008-04-01T04:26:00+00:00monthlyhttps://orangebookblog.com/2008/03/30/eisai-wins-prel/2008-07-15T16:03:00+00:00monthlyhttps://orangebookblog.com/2008/03/28/pharma-news-b-1/2008-03-29T03:59:53+00:00monthlyhttps://orangebookblog.com/2008/03/26/iqpc-optimising/2008-03-26T16:55:00+00:00monthlyhttps://orangebookblog.com/2008/03/21/federal-circu-1/2008-03-21T20:04:47+00:00monthlyhttps://orangebookblog.com/2008/03/16/pharma-news-bri-3/2008-03-17T03:54:47+00:00monthlyhttps://orangebookblog.com/2008/03/12/district-court-2/2008-03-13T04:25:58+00:00monthlyhttps://orangebookblog.com/2008/03/10/federal-circuit-3/2008-03-10T15:26:07+00:00monthlyhttps://orangebookblog.com/2008/03/07/barr-labs-preva/2008-03-08T04:19:00+00:00monthlyhttps://orangebookblog.com/2008/02/29/pharma-news-b-2/2008-03-01T03:04:00+00:00monthlyhttps://orangebookblog.com/2008/02/16/pharma-news-b-1-2/2008-02-16T22:54:55+00:00monthlyhttps://orangebookblog.com/2008/02/11/informa-life-sc-2/2008-02-12T04:33:41+00:00monthlyhttps://orangebookblog.com/2008/02/08/pharma-news-bri-4/2008-02-09T04:52:19+00:00monthlyhttps://orangebookblog.com/2008/02/06/ftc-files-amicu/2008-02-14T19:18:08+00:00monthlyhttps://orangebookblog.com/2008/02/04/fda-answers-ram/2008-02-04T16:46:00+00:00monthlyhttps://orangebookblog.com/2008/01/25/pharma-news-b-1-3/2008-01-25T16:00:07+00:00monthlyhttps://orangebookblog.com/2008/01/20/iqpc-pharmaceut/2008-01-21T04:28:47+00:00monthlyhttps://orangebookblog.com/2008/01/17/teva-seeks-reli/2008-11-23T21:41:33+00:00monthlyhttps://orangebookblog.com/2008/01/11/pharma-news-bri-5/2008-01-11T22:06:52+00:00monthlyhttps://orangebookblog.com/2007/12/28/pharma-news-b-1-4/2007-12-28T07:00:00+00:00monthlyhttps://orangebookblog.com/2007/12/26/aci-pharmabiote/2007-12-27T05:09:52+00:00monthlyhttps://orangebookblog.com/2007/12/11/pfizer-wins-dis/2007-12-12T05:57:10+00:00monthlyhttps://orangebookblog.com/2007/12/09/pharma-news-bri-6/2007-12-10T05:33:02+00:00monthlyhttps://orangebookblog.com/2007/12/05/district-court-3/2007-12-06T04:56:26+00:00monthlyhttps://orangebookblog.com/2007/11/30/pharma-news-b-2-2/2007-12-01T05:18:11+00:00monthlyhttps://orangebookblog.com/2007/11/29/lovenox-patent/2007-11-30T05:32:36+00:00monthlyhttps://orangebookblog.com/2007/11/28/dismissal-of-in/2007-11-29T04:11:13+00:00monthlyhttps://orangebookblog.com/2007/11/10/pharma-news-b-1-5/2007-11-11T05:26:11+00:00monthlyhttps://orangebookblog.com/2007/11/06/fdas-request-fo/2007-11-07T05:57:55+00:00monthlyhttps://orangebookblog.com/2007/11/02/pharma-news-bri-7/2007-11-03T04:21:55+00:00monthlyhttps://orangebookblog.com/2007/11/01/bayer-prevails/2007-11-01T23:18:30+00:00monthlyhttps://orangebookblog.com/2007/10/28/federal-circu-1-2/2007-10-29T02:21:48+00:00monthlyhttps://orangebookblog.com/2007/10/15/pharma-news-b-1-6/2007-10-16T00:06:16+00:00monthlyhttps://orangebookblog.com/2007/10/12/paddock-labs-pr/2007-10-12T17:03:34+00:00monthlyhttps://orangebookblog.com/2007/10/11/federal-circuit-4/2007-10-12T14:27:41+00:00monthlyhttps://orangebookblog.com/2007/10/10/iibig-new-direc/2007-10-10T22:36:19+00:00monthlyhttps://orangebookblog.com/2007/10/08/fda-requests-1/2007-10-09T04:58:00+00:00monthlyhttps://orangebookblog.com/2007/10/03/aci-maximizing/2007-10-04T04:55:00+00:00monthlyhttps://orangebookblog.com/2007/10/01/pharma-news-bri-8/2007-10-01T15:51:00+00:00monthlyhttps://orangebookblog.com/2007/09/25/new-features/2007-09-26T03:10:46+00:00monthlyhttps://orangebookblog.com/2007/09/23/pfizer-wins-app/2007-09-24T04:57:54+00:00monthlyhttps://orangebookblog.com/2007/09/21/pharma-news-b-2-3/2007-09-22T03:19:54+00:00monthlyhttps://orangebookblog.com/2007/09/20/no-second-bite/2007-09-21T03:11:32+00:00monthlyhttps://orangebookblog.com/2007/09/18/bio-ceo-jim-gre/2007-09-18T20:23:41+00:00monthlyhttps://orangebookblog.com/2007/09/16/pharma-news-b-1-7/2007-09-19T18:36:19+00:00monthlyhttps://orangebookblog.com/2007/09/14/teva-wins-in-di/2007-09-14T21:50:55+00:00monthlyhttps://orangebookblog.com/2007/09/11/federal-circuit-5/2007-09-13T04:05:34+00:00monthlyhttps://orangebookblog.com/2007/09/09/district-court-4/2007-09-10T03:01:52+00:00monthlyhttps://orangebookblog.com/2007/09/06/iir-8th-annual/2007-09-07T04:28:08+00:00monthlyhttps://orangebookblog.com/2007/09/05/forest-labs-lex/2007-09-06T04:54:26+00:00monthlyhttps://orangebookblog.com/2007/09/04/pharma-news-bri-9/2007-09-05T03:42:01+00:00monthlyhttps://orangebookblog.com/2007/08/27/aci-pharmabiote-2/2007-08-28T04:27:51+00:00monthlyhttps://orangebookblog.com/2007/08/21/uspto-to-presen/2007-08-21T17:45:32+00:00monthlyhttps://orangebookblog.com/2007/08/19/us-patent-offic/2007-09-05T18:08:32+00:00monthlyhttps://orangebookblog.com/2007/08/16/informa-life-sc-3/2007-08-17T00:41:40+00:00monthlyhttps://orangebookblog.com/2007/08/13/aci-fda-boot-ca-2/2007-08-14T03:10:34+00:00monthlyhttps://orangebookblog.com/2007/08/10/pharma-news-b-1-8/2007-08-13T19:13:10+00:00monthlyhttps://orangebookblog.com/2007/08/03/pharma-news-bri-10/2007-08-03T15:47:16+00:00monthlyhttps://orangebookblog.com/2007/08/01/federal-circuit-6/2007-08-01T15:51:12+00:00monthlyhttps://orangebookblog.com/2007/07/31/patent-protecti/2007-07-31T16:05:55+00:00monthlyhttps://orangebookblog.com/2007/07/30/ranbaxy-and-gsk/2007-07-30T16:17:50+00:00monthlyhttps://orangebookblog.com/2007/07/27/pharma-news-b-2-4/2007-07-27T12:05:39+00:00monthlyhttps://orangebookblog.com/2007/07/25/federal-circuit-7/2007-07-26T03:10:38+00:00monthlyhttps://orangebookblog.com/2007/07/15/pharma-news-b-1-9/2007-07-15T18:51:56+00:00monthlyhttps://orangebookblog.com/2007/07/11/apotex-prevails/2007-07-11T20:27:57+00:00monthlyhttps://orangebookblog.com/2007/07/09/scherago-intern/2007-07-10T01:37:19+00:00monthlyhttps://orangebookblog.com/2007/07/07/pharma-news-bri-11/2007-07-08T04:36:46+00:00monthlyhttps://orangebookblog.com/2007/07/05/festo-xiii-fede/2007-07-06T04:29:42+00:00monthlyhttps://orangebookblog.com/2007/07/05/aci-fda-boot-ca-3/2007-07-05T16:17:41+00:00monthlyhttps://orangebookblog.com/2007/06/29/pharma-news-b-1-10/2007-06-30T02:56:18+00:00monthlyhttps://orangebookblog.com/2007/06/28/federal-circuit-8/2007-06-29T04:19:48+00:00monthlyhttps://orangebookblog.com/2007/06/27/follow-on-biolo/2007-06-27T17:59:20+00:00monthlyhttps://orangebookblog.com/2007/06/26/senate-committe/2007-06-26T23:00:48+00:00monthlyhttps://orangebookblog.com/2007/06/25/informa-life-sc-4/2007-06-26T01:38:56+00:00monthlyhttps://orangebookblog.com/2007/06/23/pharma-news-bri-12/2007-06-23T20:01:30+00:00monthlyhttps://orangebookblog.com/2007/06/19/bristolmyers_sq/2007-06-19T15:21:26+00:00monthlyhttps://orangebookblog.com/2007/06/16/pharma_news_bri_2/2007-06-17T04:55:00+00:00monthlyhttps://orangebookblog.com/2007/06/12/teva_defeats_no/2007-06-12T15:02:59+00:00monthlyhttps://orangebookblog.com/2007/06/08/pharma_news_bri_1/2007-06-08T17:02:29+00:00monthlyhttps://orangebookblog.com/2007/06/06/district_court__1/2007-06-07T04:00:10+00:00monthlyhttps://orangebookblog.com/2007/06/05/aci_pharmabiote/2008-03-17T08:38:48+00:00monthlyhttps://orangebookblog.com/2007/06/04/district_court_/2007-06-05T03:16:24+00:00monthlyhttps://orangebookblog.com/2007/06/01/pharma_news_bri/2007-06-01T13:59:44+00:00monthlyhttps://orangebookblog.com/2007/05/28/aci_maximizing_/2007-05-29T03:21:53+00:00monthlyhttps://orangebookblog.com/2007/05/25/an_alternative_/2007-05-25T16:04:29+00:00monthlyhttps://orangebookblog.com/2007/05/24/solicitor_gener/2007-05-24T14:39:24+00:00monthlyhttps://orangebookblog.com/2007/05/23/district_court_-2/2007-05-24T15:56:54+00:00monthlyhttps://orangebookblog.com/2007/05/21/federal_circuit_1/2007-05-21T22:26:18+00:00monthlyhttps://orangebookblog.com/2007/05/20/novartis_wins_t/2007-05-21T03:33:06+00:00monthlyhttps://orangebookblog.com/2007/05/18/pharma_news_bri_1-2/2007-05-18T18:43:05+00:00monthlyhttps://orangebookblog.com/2007/05/15/eisai_defeats_d/2008-07-31T05:50:12+00:00monthlyhttps://orangebookblog.com/2007/05/13/federal_circuit/2007-05-14T03:17:44+00:00monthlyhttps://orangebookblog.com/2007/05/10/does_fda_need_a/2007-05-10T13:51:34+00:00monthlyhttps://orangebookblog.com/2007/05/03/pharma_news_bri-2/2007-05-03T14:46:42+00:00monthlyhttps://orangebookblog.com/2007/05/01/house_energy_an/2007-05-02T03:26:11+00:00monthlyhttps://orangebookblog.com/2007/05/01/aci_fda_boot_ca/2007-05-02T02:49:12+00:00monthlyhttps://orangebookblog.com/2007/04/30/district_court__1-2/2007-04-30T21:04:28+00:00monthlyhttps://orangebookblog.com/2007/04/30/supreme_court_u/2007-04-30T15:18:15+00:00monthlyhttps://orangebookblog.com/2007/04/29/pfizer_wins_att/2007-04-30T02:07:47+00:00monthlyhttps://orangebookblog.com/2007/04/26/mylan_apotex_an/2007-04-27T03:28:51+00:00monthlyhttps://orangebookblog.com/2007/04/25/pharma_news_bri_1-3/2007-04-26T03:35:05+00:00monthlyhttps://orangebookblog.com/2007/04/24/purdue_pharma_t/2007-04-25T04:21:11+00:00monthlyhttps://orangebookblog.com/2007/04/23/federal_circuit-2/2007-04-23T23:43:10+00:00monthlyhttps://orangebookblog.com/2007/04/19/abbott_wins_pre/2007-04-20T04:24:33+00:00monthlyhttps://orangebookblog.com/2007/04/18/fda_refuses_to_/2007-04-18T23:39:14+00:00monthlyhttps://orangebookblog.com/2007/04/17/followon_biolog/2007-04-17T22:17:50+00:00monthlyhttps://orangebookblog.com/2007/04/16/warner_chilcott/2007-04-17T03:30:27+00:00monthlyhttps://orangebookblog.com/2007/04/16/lsi_pharmaceuti/2007-04-17T02:04:38+00:00monthlyhttps://orangebookblog.com/2007/04/15/district_court_-3/2007-04-16T04:46:22+00:00monthlyhttps://orangebookblog.com/2007/04/10/pharma_news_bri-3/2007-04-10T22:28:33+00:00monthlyhttps://orangebookblog.com/2007/04/09/reminder_hatchw/2007-04-10T03:19:19+00:00monthlyhttps://orangebookblog.com/2007/04/05/pfizer_and_myla/2007-04-06T04:52:56+00:00monthlyhttps://orangebookblog.com/2007/03/30/federal_circuit_1-2/2007-05-11T17:57:19+00:00monthlyhttps://orangebookblog.com/2007/03/29/merck_prevails_/2007-03-29T16:05:18+00:00monthlyhttps://orangebookblog.com/2007/03/28/pharma_news_bri_1-4/2007-03-29T02:58:53+00:00monthlyhttps://orangebookblog.com/2007/03/27/mylan_obtains_i/2007-03-27T15:14:55+00:00monthlyhttps://orangebookblog.com/2007/03/26/aci_paragraph_i/2007-03-27T03:22:25+00:00monthlyhttps://orangebookblog.com/2007/03/25/house_oversight/2007-03-26T01:20:04+00:00monthlyhttps://orangebookblog.com/2007/03/23/mylan_launches_/2007-03-26T17:11:22+00:00monthlyhttps://orangebookblog.com/2007/03/22/federal_circuit-3/2007-03-23T04:57:21+00:00monthlyhttps://orangebookblog.com/2007/03/20/pfizer_defeats_/2007-03-21T04:47:25+00:00monthlyhttps://orangebookblog.com/2007/03/16/news_from_phrma/2007-03-18T19:25:12+00:00monthlyhttps://orangebookblog.com/2007/03/15/decision_on_tam_1/2007-03-16T01:04:01+00:00monthlyhttps://orangebookblog.com/2007/03/14/aci_3rd_annual_/2007-03-14T22:15:43+00:00monthlyhttps://orangebookblog.com/2007/03/12/fda_law_blog_go/2007-03-13T00:52:04+00:00monthlyhttps://orangebookblog.com/2007/03/09/pharma_news_bri-4/2007-03-09T18:59:53+00:00monthlyhttps://orangebookblog.com/2007/03/08/senate_committe_1/2007-03-09T04:09:51+00:00monthlyhttps://orangebookblog.com/2007/03/05/senate_committe/2007-03-06T04:05:34+00:00monthlyhttps://orangebookblog.com/2007/03/04/apotex_and_its_/2007-03-06T18:05:22+00:00monthlyhttps://orangebookblog.com/2007/03/03/news_from_gpha_/2007-03-03T20:20:29+00:00monthlyhttps://orangebookblog.com/2007/03/02/lsi_pharmaceuti-2/2007-03-03T05:19:32+00:00monthlyhttps://orangebookblog.com/2007/02/28/pfizer_successf/2007-02-28T06:27:53+00:00monthlyhttps://orangebookblog.com/2007/02/27/astellas_and_bo/2007-04-07T11:30:16+00:00monthlyhttps://orangebookblog.com/2007/02/26/federal_circuit-4/2007-02-28T20:15:59+00:00monthlyhttps://orangebookblog.com/2007/02/22/thailands_compu/2007-02-24T08:43:31+00:00monthlyhttps://orangebookblog.com/2007/02/20/is_a_patent_tha/2007-02-21T15:32:29+00:00monthlyhttps://orangebookblog.com/2007/02/18/economic_benefi/2007-02-18T23:14:23+00:00monthlyhttps://orangebookblog.com/2007/02/15/bill_aimed_at_p/2007-02-15T21:53:09+00:00monthlyhttps://orangebookblog.com/2007/02/15/followon_biolog-2/2007-02-15T17:29:39+00:00monthlyhttps://orangebookblog.com/2007/02/15/district_court_-4/2008-07-22T08:43:18+00:00monthlyhttps://orangebookblog.com/2007/02/12/watson_pharmace/2007-02-13T05:37:36+00:00monthlyhttps://orangebookblog.com/2007/02/11/amphastar_and_t/2007-02-12T04:27:06+00:00monthlyhttps://orangebookblog.com/2007/02/08/iqpc_pharmaceut/2007-02-09T04:40:28+00:00monthlyhttps://orangebookblog.com/2007/02/07/ftc_pursues_ant/2007-02-07T21:10:06+00:00monthlyhttps://orangebookblog.com/2007/02/06/aci_fda_boot_ca-2/2007-02-07T03:51:08+00:00monthlyhttps://orangebookblog.com/2007/02/04/pharma_news_bri-5/2007-02-21T05:45:56+00:00monthlyhttps://orangebookblog.com/2007/02/01/pfizer_wins_aga/2007-02-01T22:04:16+00:00monthlyhttps://orangebookblog.com/2007/02/01/senators_reintr/2007-02-01T06:02:48+00:00monthlyhttps://orangebookblog.com/2007/01/31/apotex_tries_ag/2007-02-02T20:23:19+00:00monthlyhttps://orangebookblog.com/2007/01/29/ranbaxy_appeals/2007-03-29T07:08:44+00:00monthlyhttps://orangebookblog.com/2007/01/24/generic_vs_gene/2007-01-25T05:59:37+00:00monthlyhttps://orangebookblog.com/2007/01/22/ondansetron_upd/2007-01-23T05:50:50+00:00monthlyhttps://orangebookblog.com/2007/01/21/caraco_wins_app/2007-01-22T04:53:33+00:00monthlyhttps://orangebookblog.com/2007/01/18/ftc_commissione/2007-01-18T18:57:23+00:00monthlyhttps://orangebookblog.com/2007/01/17/celgenes_day_in/2007-01-17T21:23:30+00:00monthlyhttps://orangebookblog.com/2007/01/15/senate_judiciar/2007-01-15T23:21:38+00:00monthlyhttps://orangebookblog.com/2007/01/14/ethyol_case_bet/2007-01-15T05:47:01+00:00monthlyhttps://orangebookblog.com/2007/01/11/biovail_fights_/2007-01-11T22:52:16+00:00monthlyhttps://orangebookblog.com/2007/01/10/abbott_labs_und/2007-01-11T04:56:09+00:00monthlyhttps://orangebookblog.com/2007/01/09/supreme_court_r/2007-01-09T16:19:42+00:00monthlyhttps://orangebookblog.com/2007/01/08/lsis_biotechnol/2007-01-08T17:43:03+00:00monthlyhttps://orangebookblog.com/2007/01/07/federal_circuit-5/2007-01-08T05:55:25+00:00monthlyhttps://orangebookblog.com/2007/01/06/new_academic_wo/2007-01-06T19:52:00+00:00monthlyhttps://orangebookblog.com/2007/01/05/savient_loses_m/2007-01-06T05:49:16+00:00monthlyhttps://orangebookblog.com/2007/01/04/acis_3rd_nation/2007-01-04T20:33:00+00:00monthlyhttps://orangebookblog.com/2006/12/27/lilly_prevails_/2006-12-27T06:56:35+00:00monthlyhttps://orangebookblog.com/2006/12/26/pharmabiotech_i/2006-12-27T05:58:31+00:00monthlyhttps://orangebookblog.com/2006/12/21/district_court_-5/2006-12-22T05:47:12+00:00monthlyhttps://orangebookblog.com/2006/12/17/in_re_tamoxifen/2006-12-18T05:51:05+00:00monthlyhttps://orangebookblog.com/2006/12/14/pharmacies_sue_/2006-12-15T15:49:54+00:00monthlyhttps://orangebookblog.com/2006/12/12/federal_circuit_2/2006-12-13T05:56:00+00:00monthlyhttps://orangebookblog.com/2006/12/10/federal_circuit_1-3/2006-12-11T04:47:19+00:00monthlyhttps://orangebookblog.com/2006/12/08/overseas_sales_/2006-12-09T00:22:07+00:00monthlyhttps://orangebookblog.com/2006/12/06/federal_circuit-6/2006-12-07T04:43:25+00:00monthlyhttps://orangebookblog.com/2006/11/26/fda_delay_in_re/2006-11-27T17:05:09+00:00monthlyhttps://orangebookblog.com/2006/11/20/federal_circuit_2-2/2006-11-21T05:57:09+00:00monthlyhttps://orangebookblog.com/2006/11/14/dc_circuit_agre/2006-11-14T19:16:16+00:00monthlyhttps://orangebookblog.com/2006/11/13/apotex_sues_fda/2006-11-14T14:13:08+00:00monthlyhttps://orangebookblog.com/2006/11/09/federal_circuit_1-4/2007-05-04T13:56:50+00:00monthlyhttps://orangebookblog.com/2006/11/02/federal_circuit-7/2006-11-03T05:50:57+00:00monthlyhttps://orangebookblog.com/2006/11/01/paddock_labs_wi/2006-11-02T04:06:32+00:00monthlyhttps://orangebookblog.com/2006/10/31/eisai_wins_one_/2006-11-01T03:30:07+00:00monthlyhttps://orangebookblog.com/2006/10/30/supreme_court_d_1/2006-10-30T17:35:21+00:00monthlyhttps://orangebookblog.com/2006/10/29/kv_pharma_files/2006-10-30T03:43:08+00:00monthlyhttps://orangebookblog.com/2006/10/25/hoffmanlaroches/2006-10-25T09:30:08+00:00monthlyhttps://orangebookblog.com/2006/10/24/jj_wins_prelimi/2006-10-25T04:55:59+00:00monthlyhttps://orangebookblog.com/2006/10/23/ftc_and_warner_/2006-10-24T01:10:17+00:00monthlyhttps://orangebookblog.com/2006/10/23/federal_circuit-8/2006-10-24T00:46:37+00:00monthlyhttps://orangebookblog.com/2006/10/20/fda_announces_n/2006-10-20T23:11:31+00:00monthlyhttps://orangebookblog.com/2006/10/19/mylan_wins_moti/2006-10-20T04:50:00+00:00monthlyhttps://orangebookblog.com/2006/10/19/court_dismisses/2007-03-28T13:17:31+00:00monthlyhttps://orangebookblog.com/2006/10/17/janssen_wins_tr/2006-10-18T04:58:40+00:00monthlyhttps://orangebookblog.com/2006/10/16/pharmaceutical_/2006-10-17T02:58:00+00:00monthlyhttps://orangebookblog.com/2006/10/12/reminder_maximi/2006-10-13T04:53:15+00:00monthlyhttps://orangebookblog.com/2006/10/10/supreme_court_d/2006-10-11T04:02:30+00:00monthlyhttps://orangebookblog.com/2006/10/09/sens_kohl_and_l/2006-10-10T04:59:43+00:00monthlyhttps://orangebookblog.com/2006/10/09/fda_announces_i/2006-10-10T04:48:23+00:00monthlyhttps://orangebookblog.com/2006/10/03/rep_waxman_and_/2006-10-03T05:12:46+00:00monthlyhttps://orangebookblog.com/2006/09/28/ftc_seeks_to_co/2006-09-29T04:44:20+00:00monthlyhttps://orangebookblog.com/2006/09/26/pfizer_advises_/2006-09-27T03:27:00+00:00monthlyhttps://orangebookblog.com/2006/09/24/takeda_wins_att/2006-09-24T17:00:00+00:00monthlyhttps://orangebookblog.com/2006/09/21/federal_circuit-9/2006-09-22T04:41:00+00:00monthlyhttps://orangebookblog.com/2006/09/20/rep_waxman_anno/2006-09-21T04:56:23+00:00monthlyhttps://orangebookblog.com/2006/09/19/reverse_payment/2006-09-19T11:59:38+00:00monthlyhttps://orangebookblog.com/2006/09/18/alza_loses_appe/2006-09-19T03:15:54+00:00monthlyhttps://orangebookblog.com/2006/09/17/pfizers_patent_/2006-09-18T04:29:06+00:00monthlyhttps://orangebookblog.com/2006/09/14/aba_section_of_/2006-09-15T03:35:52+00:00monthlyhttps://orangebookblog.com/2006/09/11/astra_zeneca_li/2006-09-12T04:52:41+00:00monthlyhttps://orangebookblog.com/2006/08/31/authorized_gene/2006-08-31T16:45:29+00:00monthlyhttps://orangebookblog.com/2006/08/31/lipitor_worldwi/2006-08-31T16:18:14+00:00monthlyhttps://orangebookblog.com/2006/08/28/purdue_and_endo/2007-04-22T22:12:46+00:00monthlyhttps://orangebookblog.com/2006/08/24/by_david_harper/2006-08-25T04:58:15+00:00monthlyhttps://orangebookblog.com/2006/08/21/pfizer_victorio/2006-08-21T16:30:12+00:00monthlyhttps://orangebookblog.com/2006/08/17/new_paper_on_au/2006-08-18T22:05:21+00:00monthlyhttps://orangebookblog.com/2006/08/14/strategic_plann/2006-08-15T04:14:09+00:00monthlyhttps://orangebookblog.com/2006/08/10/maximizing_phar/2006-08-11T01:25:56+00:00monthlyhttps://orangebookblog.com/2006/08/08/apotex_launches/2006-08-08T16:34:41+00:00monthlyhttps://orangebookblog.com/2006/08/06/abbott_and_teva/2007-08-14T22:08:49+00:00monthlyhttps://orangebookblog.com/2006/08/02/viropharma_purs/2006-08-03T03:42:33+00:00monthlyhttps://orangebookblog.com/2006/07/31/gpha_releases_i/2006-08-01T03:38:37+00:00monthlyhttps://orangebookblog.com/2006/07/25/fda_updates_sta/2006-07-26T02:55:47+00:00monthlyhttps://orangebookblog.com/2006/07/24/senators_introd/2006-07-25T04:21:37+00:00monthlyhttps://orangebookblog.com/2006/07/21/ftc_commissione-2/2006-07-21T12:21:52+00:00monthlyhttps://orangebookblog.com/2006/07/16/district_court_-6/2006-07-17T04:59:44+00:00monthlyhttps://orangebookblog.com/2006/07/12/sandozs_motion_/2006-07-13T03:16:23+00:00monthlyhttps://orangebookblog.com/2006/07/06/apotex_accuses_/2006-07-06T23:28:07+00:00monthlyhttps://orangebookblog.com/2006/07/05/fourth_circuit_/2006-07-06T03:50:22+00:00monthlyhttps://orangebookblog.com/2006/07/01/pfizer_subsidia/2006-07-01T05:38:26+00:00monthlyhttps://orangebookblog.com/2006/06/30/by_david_s_harp/2007-05-13T22:52:46+00:00monthlyhttps://orangebookblog.com/2006/06/28/senators_introd-2/2006-06-29T04:31:32+00:00monthlyhttps://orangebookblog.com/2006/06/27/phrma_study_fin/2006-06-28T03:58:39+00:00monthlyhttps://orangebookblog.com/2006/06/26/supreme_court_d_1-2/2006-06-26T15:59:01+00:00monthlyhttps://orangebookblog.com/2006/06/25/fda_appeals_omn/2006-06-26T03:54:59+00:00monthlyhttps://orangebookblog.com/2006/06/23/fda_grants_fina/2006-06-23T18:34:03+00:00monthlyhttps://orangebookblog.com/2006/06/23/federal_circuit_1-5/2006-06-23T16:23:35+00:00monthlyhttps://orangebookblog.com/2006/06/22/sandoz_requests/2006-06-23T02:34:05+00:00monthlyhttps://orangebookblog.com/2006/06/22/merck_launches_/2006-06-22T19:16:57+00:00monthlyhttps://orangebookblog.com/2006/06/21/bill_proposed_i/2006-06-22T03:50:04+00:00monthlyhttps://orangebookblog.com/2006/06/19/ftc_files_suppl/2006-06-20T03:01:50+00:00monthlyhttps://orangebookblog.com/2006/06/19/supreme_court_d-2/2006-06-19T17:22:42+00:00monthlyhttps://orangebookblog.com/2006/06/18/sdny_orange_boo/2006-06-19T03:07:54+00:00monthlyhttps://orangebookblog.com/2006/06/13/merck_and_integ/2006-06-14T03:05:37+00:00monthlyhttps://orangebookblog.com/2006/06/12/barr_labs_pays_/2006-06-13T03:26:13+00:00monthlyhttps://orangebookblog.com/2006/06/08/ftc_publishes_p/2006-06-08T12:52:37+00:00monthlyhttps://orangebookblog.com/2006/06/07/federal_circuit-10/2006-06-07T16:51:49+00:00monthlyhttps://orangebookblog.com/2006/06/06/tevas_victory_a/2006-06-09T16:14:14+00:00monthlyhttps://orangebookblog.com/2006/06/04/fda_releases_om/2006-06-04T23:27:00+00:00monthlyhttps://orangebookblog.com/2006/06/01/fda_approves_fi/2006-06-01T10:21:17+00:00monthlyhttps://orangebookblog.com/2006/05/31/antitrust_case_/2008-04-11T13:45:47+00:00monthlyhttps://orangebookblog.com/2006/05/29/sen_leahy_propo/2006-05-30T03:20:12+00:00monthlyhttps://orangebookblog.com/2006/05/28/fda_appeals_dec/2006-05-28T17:27:55+00:00monthlyhttps://orangebookblog.com/2006/05/26/reverse_payment-2/2006-05-27T04:34:16+00:00monthlyhttps://orangebookblog.com/2006/05/24/fda_approves_te/2006-05-24T22:07:40+00:00monthlyhttps://orangebookblog.com/2006/05/23/solicitor_gener-2/2006-05-24T00:21:54+00:00monthlyhttps://orangebookblog.com/2006/05/21/gsk_may_be_on_t/2006-05-22T04:17:50+00:00monthlyhttps://orangebookblog.com/2006/05/19/doj_advises_sup/2006-05-19T13:28:40+00:00monthlyhttps://orangebookblog.com/2006/05/17/ivax_and_ranbax/2006-05-17T07:32:03+00:00monthlyhttps://orangebookblog.com/2006/05/16/supreme_court_a/2006-05-17T02:09:15+00:00monthlyhttps://orangebookblog.com/2006/05/14/merck_seeks_to_/2006-05-15T03:52:33+00:00monthlyhttps://orangebookblog.com/2006/05/11/eli_lilly_files/2006-05-11T15:00:47+00:00monthlyhttps://orangebookblog.com/2006/05/10/public_comment_/2006-05-11T04:40:00+00:00monthlyhttps://orangebookblog.com/2006/05/09/ftc_commissione-3/2006-05-10T03:46:00+00:00monthlyhttps://orangebookblog.com/2006/05/09/welcome_to_oran/2006-05-18T13:11:49+00:00monthlyhttps://orangebookblog.comdaily1.02026-04-30T19:16:00+00:00